2666-5247

The Lancet Microbe

Elsevier

View prefix report (10.1016)

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 1418 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact1418 DOIs
2

Attach ORCID iDs across 893 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact893 DOIs
3

Deposit reference lists for 284 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact284 DOIs

DOIs for this ISSN

Showing the top 5 of 1418 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 WHO's Global Tuberculosis Report 2022 (10.1016/s2666-5247(22)00359-7)
Abstract References ORCID
226.15 1035
2 The 2023 WHO World malaria report (10.1016/s2666-5247(24)00016-8)
Abstract References ORCID
188.09 321
3 WHO publishes updated list of bacterial priority pathogens (10.1016/j.lanmic.2024.07.003)
Abstract References ORCID
180.74 256
4 WHO world malaria report 2024 (10.1016/j.lanmic.2025.101073)
Abstract References ORCID
165.51 160
5 Stability of SARS-CoV-2 in different environmental condition… (10.1016/s2666-5247(20)30003-3)
Abstract ORCID
156.39 1341
6 SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, dura… (10.1016/s2666-5247(20)30172-5)
Abstract ORCID
153.45 1171
7 First RSV vaccine approvals (10.1016/s2666-5247(23)00195-7)
Abstract References ORCID
145.09 85
8 Comparative tropism, replication kinetics, and cell damage p… (10.1016/s2666-5247(20)30004-5)
Abstract ORCID
142.99 723
9 COVID-19 testing in Africa: lessons learnt (10.1016/s2666-5247(20)30068-9)
Abstract References ORCID
140.19 73
10 Neutralising antibody titres as predictors of protection aga… (10.1016/s2666-5247(21)00267-6)
Abstract ORCID
137.79 569
11 India grapples with second wave of COVID-19 (10.1016/s2666-5247(21)00123-3)
Abstract References ORCID
135.97 64
12 WHO launches global initiative for arboviral diseases (10.1016/s2666-5247(22)00130-6)
Abstract References ORCID
134.43 61
13 Viral presence and immunopathology in patients with lethal C… (10.1016/s2666-5247(20)30144-0)
Abstract ORCID
133.70 471
14 Histopathological findings and viral tropism in UK patients… (10.1016/s2666-5247(20)30115-4)
Abstract ORCID
133.60 469
15 SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an ex… (10.1016/s2666-5247(20)30089-6)
Abstract ORCID
132.66 449
16 The emergence of COVID-19 associated mucormycosis: a review… (10.1016/s2666-5247(21)00237-8)
Abstract ORCID
129.27 384
17 SARS-CoV-2 spike E484K mutation reduces antibody neutralisat… (10.1016/s2666-5247(21)00068-9)
Abstract ORCID
128.99 379
18 COVID-19 vaccines: the pandemic will not end overnight (10.1016/s2666-5247(20)30226-3)
Abstract References ORCID
128.70 51
19 Dynamics of SARS-CoV-2 neutralising antibody responses and d… (10.1016/s2666-5247(21)00025-2)
Abstract ORCID
127.75 358
20 The gut mycobiome in health, disease, and clinical applicati… (10.1016/s2666-5247(22)00203-8)
Abstract ORCID
126.95 345
21 WHO publish fungal priority pathogens list (10.1016/s2666-5247(23)00003-4)
Abstract References ORCID
126.09 47
22 Global epidemiology and clinical outcomes of carbapenem-resi… (10.1016/s2666-5247(22)00329-9)
Abstract ORCID
123.34 292
23 Co-infections: potentially lethal and unexplored in COVID-19 (10.1016/s2666-5247(20)30009-4)
Abstract ORCID
123.12 289
24 The 2021 WHO catalogue of Mycobacterium tuberculosis complex… (10.1016/s2666-5247(21)00301-3)
Abstract ORCID
122.74 284
25 Comparison of seven commercial SARS-CoV-2 rapid point-of-car… (10.1016/s2666-5247(21)00056-2)
Abstract ORCID
122.05 275
26 Africa's $100-million Pathogen Genomics Initiative (10.1016/s2666-5247(20)30206-8)
Abstract References ORCID
121.74 41
27 An integrated national scale SARS-CoV-2 genomic surveillance… (10.1016/s2666-5247(20)30054-9)
Abstract ORCID
121.65 270
28 Co-infections, secondary infections, and antimicrobial use i… (10.1016/s2666-5247(21)00090-2)
Abstract ORCID
121.57 269
29 Infection and co-infection patterns of community-acquired pn… (10.1016/s2666-5247(23)00031-9)
Abstract ORCID
120.75 259
30 WHO global antimicrobial resistance surveillance for Neisser… (10.1016/s2666-5247(21)00171-3)
Abstract ORCID
120.50 256
31 Mycoplasma pneumoniae: delayed re-emergence after COVID-19 p… (10.1016/s2666-5247(23)00344-0)
Abstract ORCID
119.81 248
32 Interference between rhinovirus and influenza A virus: a cli… (10.1016/s2666-5247(20)30114-2)
Abstract ORCID
119.55 245
33 Africa's struggle with inadequate COVID-19 testing (10.1016/s2666-5247(20)30014-8)
Abstract References ORCID
119.33 38
34 Wastewater concentrations of human influenza, metapneumoviru… (10.1016/s2666-5247(22)00386-x)
Abstract ORCID
118.55 234
35 Worldwide emergence of fluconazole-resistant Candida parapsi… (10.1016/s2666-5247(23)00067-8)
Abstract ORCID
117.80 226
36 Avian influenza spillover into mammals (10.1016/s2666-5247(23)00173-8)
Abstract References ORCID
116.72 35
37 Mass testing for COVID-19 (10.1016/s2666-5247(20)30205-6)
Abstract References ORCID
113.89 32
38 Emergence of resistant Candida auris (10.1016/s2666-5247(23)00143-x)
Abstract References ORCID
113.89 32
39 The durability of immunity against reinfection by SARS-CoV-2… (10.1016/s2666-5247(21)00219-6)
Abstract ORCID
112.52 177
40 The role of bacterial vaccines in the fight against antimicr… (10.1016/s2666-5247(22)00303-2)
Abstract ORCID
112.40 176
41 Diagnosing COVID-19-associated pulmonary aspergillosis (10.1016/s2666-5247(20)30027-6)
Abstract ORCID
111.39 168
42 SARS-CoV-2-specific antibody and T-cell responses 1 year aft… (10.1016/s2666-5247(22)00036-2)
Abstract ORCID
111.39 168
43 COVID-19 vaccine efficacy and effectiveness—the elephant (no… (10.1016/s2666-5247(21)00069-0)
Abstract ORCID
110.87 164
44 Genomic surveillance to combat COVID-19: challenges and oppo… (10.1016/s2666-5247(21)00121-x)
Abstract ORCID
110.87 164
45 Human infection of avian influenza A H3N8 virus and the vira… (10.1016/s2666-5247(22)00192-6)
Abstract ORCID
110.21 159
46 Preliminary phase 1 results from an HIV vaccine candidate tr… (10.1016/s2666-5247(21)00042-2)
Abstract References ORCID
109.68 28
47 Antimicrobial resistance in patients with COVID-19: a system… (10.1016/s2666-5247(22)00355-x)
Abstract ORCID
108.95 150
48 Definition of a genetic relatedness cutoff to exclude recent… (10.1016/s2666-5247(20)30149-x)
Abstract ORCID
108.80 149
49 Worrying global decline in measles immunisation (10.1016/s2666-5247(21)00335-9)
Abstract References ORCID
107.35 26
50 T-cell and antibody responses to first BNT162b2 vaccine dose… (10.1016/s2666-5247(21)00275-5)
Abstract ORCID
107.31 139